94 related articles for article (PubMed ID: 22037511)
41. Drug interactions with tacrolimus.
van Gelder T
Drug Saf; 2002; 25(10):707-12. PubMed ID: 12167066
[TBL] [Abstract][Full Text] [Related]
42. Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa.
Bains RK; Kovacevic M; Plaster CA; Tarekegn A; Bekele E; Bradman NN; Thomas MG
BMC Genet; 2013 May; 14():34. PubMed ID: 23641907
[TBL] [Abstract][Full Text] [Related]
43. Pharmacogenomics of immunosuppressive drug metabolism.
Fredericks S; Holt DW
Curr Opin Nephrol Hypertens; 2003 Nov; 12(6):607-13. PubMed ID: 14564197
[TBL] [Abstract][Full Text] [Related]
44. A dual functional probe for assessing human CYP450 3A5 and 3A enzymes bioactivities.
Yan F; Cui Y; An Y; Ning J; Zhao X; Feng L; Huo X; Wang C; Lv C; Ma X; Tian X
Future Med Chem; 2019 Nov; 11(22):2891-2903. PubMed ID: 31702381
[No Abstract] [Full Text] [Related]
45. Translational pharmacogenetics and risk management in the cardiovascular arena: CYP3A5*3 model for gene-based drug selection.
Wilke RA
Per Med; 2006 Nov; 3(4):385-390. PubMed ID: 29788593
[TBL] [Abstract][Full Text] [Related]
46. Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation.
Ng FL; Holt DW; MacPhee IA
Expert Opin Pharmacother; 2007 Sep; 8(13):2045-58. PubMed ID: 17714059
[TBL] [Abstract][Full Text] [Related]
47. Individualized immunosuppression in transplant patients: potential role of pharmacogenetics.
Abboudi H; Macphee IA
Pharmgenomics Pers Med; 2012; 5():63-72. PubMed ID: 23226063
[TBL] [Abstract][Full Text] [Related]
48. Posttransplantation tuberculosis management in terms of immunosuppressant cost: a case report in Myanmar.
Lwin PW; Htun YY; Myint AK; Swe HK
Korean J Transplant; 2021 Mar; 35(1):48-52. PubMed ID: 35769623
[TBL] [Abstract][Full Text] [Related]
49. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.
Birdwell KA; Decker B; Barbarino JM; Peterson JF; Stein CM; Sadee W; Wang D; Vinks AA; He Y; Swen JJ; Leeder JS; van Schaik R; Thummel KE; Klein TE; Caudle KE; MacPhee IA
Clin Pharmacol Ther; 2015 Jul; 98(1):19-24. PubMed ID: 25801146
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics, Pharmacodynamics, and Side Effects of Midazolam: A Review and Case Example.
Peter JU; Dieudonné P; Zolk O
Pharmaceuticals (Basel); 2024 Apr; 17(4):. PubMed ID: 38675433
[TBL] [Abstract][Full Text] [Related]
51. Association of CYP3A4-392A/G, CYP3A5-6986A/G, and ABCB1-3435C/T Polymorphisms with Tacrolimus Dose, Serum Concentration, and Biochemical Parameters in Mexican Patients with Kidney Transplant.
Alatorre-Moreno EV; Saldaña-Cruz AM; Pérez-Guerrero EE; Morán-Moguel MC; Contreras-Haro B; López-de La Mora DA; Dávalos-Rodríguez IP; Marín-Medina A; Rivera-Cameras A; Balderas-Peña LA; Gómez-Ramos JJ; Cortés-Sanabria L; Salazar-Páramo M
Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674430
[TBL] [Abstract][Full Text] [Related]
52. GRWR Correlates with the Metabolism of Tacrolimus after Pediatric Living Donor Liver Transplantation According to Donor CYP3A5 Polymorphism.
Wan P; Hou Y; Qiu B; Feng M; Yang T; Luo Y; Xia L; Chen X; Zhang J; Xue F; Xia Q
Biomed Res Int; 2022; 2022():7647754. PubMed ID: 36349313
[TBL] [Abstract][Full Text] [Related]
53. HNF1A, KRT81, and CYP3A5: three more straws on the back of pancreatic cancer?
Scott AJ; Wilkinson JC
Transl Cancer Res; 2016 Aug; 5(Suppl 2):S253-S256. PubMed ID: 30581769
[No Abstract] [Full Text] [Related]
54. Modification of single-nucleotide polymorphism in a fully humanized CYP3A mouse by genome editing technology.
Abe S; Kobayashi K; Oji A; Sakuma T; Kazuki K; Takehara S; Nakamura K; Okada A; Tsukazaki Y; Senda N; Honma K; Yamamoto T; Ikawa M; Chiba K; Oshimura M; Kazuki Y
Sci Rep; 2017 Nov; 7(1):15189. PubMed ID: 29123154
[TBL] [Abstract][Full Text] [Related]
55. Investigation of CYP 3A5 and ABCB1 gene polymorphisms in the long-term following renal transplantation: Effects on tacrolimus exposure and kidney function.
Stefanović NZ; Cvetković TP; Jevtović-Stoimenov TM; Ignjatović AM; Paunović GJ; Veličković RM
Exp Ther Med; 2015 Sep; 10(3):1149-1156. PubMed ID: 26622455
[TBL] [Abstract][Full Text] [Related]
56. An omics investigation into chronic widespread musculoskeletal pain reveals epiandrosterone sulfate as a potential biomarker.
Livshits G; Macgregor AJ; Gieger C; Malkin I; Moayyeri A; Grallert H; Emeny RT; Spector T; Kastenmüller G; Williams FMK
Pain; 2015 Oct; 156(10):1845-1851. PubMed ID: 25915148
[TBL] [Abstract][Full Text] [Related]
57. Expression of P450 and nuclear receptors in normal and end-stage Chinese livers.
Chen H; Shen ZY; Xu W; Fan TY; Li J; Lu YF; Cheng ML; Liu J
World J Gastroenterol; 2014 Jul; 20(26):8681-90. PubMed ID: 25024626
[TBL] [Abstract][Full Text] [Related]
58. Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes.
Lee JS; Cheong HS; Kim LH; Kim JO; Seo DW; Kim YH; Chung MW; Han SY; Shin HD
Korean J Physiol Pharmacol; 2013 Dec; 17(6):479-84. PubMed ID: 24381495
[TBL] [Abstract][Full Text] [Related]
59. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.
Hesselink DA; Bouamar R; Elens L; van Schaik RH; van Gelder T
Clin Pharmacokinet; 2014 Feb; 53(2):123-39. PubMed ID: 24249597
[TBL] [Abstract][Full Text] [Related]
60. Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.
Elens L; Bouamar R; Shuker N; Hesselink DA; van Gelder T; van Schaik RH
Br J Clin Pharmacol; 2014 Apr; 77(4):715-28. PubMed ID: 24118098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
